7-chloro-1,3-dihydro-3-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one | 4699-82-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: 7-chloro-1,3-dihydro-3-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one
• 英文别名: 7-Chlor-3-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepinon-(2)；7-Chloro-3-methyl-5-phenyl-2-oxo-2,3-dihydro-1H-benzo[f]-1,4-diazepine；Ro 5-2751；7-chloro-3-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one；7-chloro-3-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
• CAS: 4699-82-5
• 化学式: C₁₆H₁₃ClN₂O
• 分子量: 284.745
• InChiKey: SATGIBNNISQKBG-UHFFFAOYSA-N

物化性质

• 熔点：
  217-219 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  453.7±45.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)
• 溶解度：
  DMF：2mg/mL； DMSO：1mg/mL；乙醇：微溶； PBS（pH 7.2）：0.25 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  41.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7-chloro-1,3-dihydro-3-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one 在 吡啶 、 diphosphorus pentasulfide 作用下， 以 四氢呋喃 、 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 为溶剂， 生成 7-chloro-3-methyl-5-phenyl-2-[(1-methyl-2-propynyl)amino]-3H-1,4-benzodiazepine
  参考文献：
  名称：

  2-(2-Alkynylamino)-3H-1,4-benzodiazepines

  摘要：

  新型6-取代的4H-咪唑[1,2-a][1,4]苯二氮杂环己烷，中间体5-取代的2-(2-炔基氨基)-3H-1,4-苯二氮杂环己烷，其药理学上可接受的酸盐，以及它们的生产工艺。本发明的化合物及其药理学上可接受的酸盐是中枢神经系统抑制剂。它们可用作镇静剂、催眠药、镇定剂、肌肉松弛剂和抗惊厥剂，还可作为增加家畜和家禽生长速度和饲料效率、哺乳动物种类的产奶量和禽类种类的产蛋量的饲料添加剂。

  公开号：

  US03933794A1
• 作为产物：
  描述：

  2-(1-Aminoethyl)-5-chlor-3-phenylindol 以75%的产率得到
  参考文献：
  名称：

  INABA S.; ISHIZUMI K.; OKAMOTO T.; YAMAMOTO H., CHEM. AND PHARM. BULL. , 1975, 23, NO 12, 3279-3282

  摘要：

  DOI：

文献信息

• 1-(Aminoalkyl)-6-aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines with antianxiety and antidepressant activity
  作者：Jackson B. Hester、Allan D. Rudzik、Philip F. Von Voigtlander

  DOI：10.1021/jm00178a009

  日期：1980.4

  A series of 1-(aminoalkyl)-6-aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines has been prepared and evaluated for central nervous system activity. We have found that members of this series have activity in pharmacological test systems designed to detect both anxiolytic and antidepressant activity. Each type of activity could be varied independently by appropriate substituent selections.

  已经制备了一系列的1-（氨基烷基）-6-芳基-4H-s-三唑并[4，3-a] [1，4]苯并二氮杂并评估中枢神经系统活性。我们发现该系列的成员在旨在检测抗焦虑和抗抑郁活性的药理学测试系统中具有活性。每种类型的活性可以通过适当的取代基选择独立地变化。
• Preparation of a New Chiral Stationary Phase Based on Macrocyclic Amide Chiral Selector for the Liquid Chromatographic Chiral Separations
  作者：Ji Yeong Sung、Seung Hyuck Choi、Myung Ho Hyun

  DOI：10.1002/chir.22569

  日期：2016.3

  A new chiral stationary phase (CSP) based on macrocyclic amide receptor was prepared starting from (1R,2R)‐1,2‐diphenylethylenediamine. The new CSP was successfully applied to the resolution of various N‐(substituted benzoyl)‐α‐amino amides with reasonably good separation factors and resolutions (α = 1.75 ~ 2.97 and RS = 2.89 ~ 6.82 for 16 analytes). The new CSP was also applied to the resolution of

  从（1R，2R）-1,2-二苯乙二胺开始制备基于大环酰胺受体的手性固定相（CSP）。新的CSP被成功地用于分离各种N-（取代的苯甲酰基）-α-氨基酰胺，具有相当好的分离系数和分离度（ 16种分析物的α= 1.75〜2.97和R S = 2.89〜6.82）。新的CSP还可用于3取代的1,4-苯并二氮杂-2-酮和一些利尿手性药物的拆分，包括苯达氟甲酰肼，甲基氯噻嗪和甲硝唑。3-取代的1,4-苯并二氮杂-2-酮和一些利尿手性药物的拆分结果也相当不错。手性28：253–258，2016。©2016 Wiley Periodicals，Inc.
• [EN] METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS<br/>[FR] PROCEDES D'UTILISATION D'INHIBITEURS DE RECAPTAGE DE LA DOPAMINE ET COMPOSITIONS CONTENANT CES DERNIERS
  申请人：SEPRACOR INC

  公开号：WO2000010551A2

  公开（公告）日：2000-03-02

  Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites like desmethylsibutramine and didesmethylsibutramine and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3, antagonists.

  本发明涉及治疗和预防多种疾病和症状的方法，包括但不限于勃起功能障碍、情感障碍、体重增加、脑功能障碍、疼痛、强迫症、物质滥用、慢性疾病、焦虑、进食障碍、偏头痛和失禁。该方法包括给予多巴胺再摄取抑制剂和可选的其他药理活性化合物。还公开了包含多巴胺再摄取抑制剂和可选的其他药理活性化合物的制药组合物和剂型。优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布曲明代谢物，如去甲基西布曲明和二去甲基西布曲明及其药学上可接受的盐、溶剂和包合物。优选的其他药理活性化合物包括影响中枢神经系统的药物，如5-HT3拮抗剂。
• Triazolo-benzodiazepine-1-ethanamines as diuretics
  申请人：The Upjohn Company

  公开号：US04689413A1

  公开（公告）日：1987-08-25

  Triazolo-benzodiazepine-1-ethanamines of the formulas ##STR1## where R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and Ring A are as defined in the specification, e.g., 8-chloro-N,N-dimethyl-.beta.,6-diphenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benz odiazepine-1-ethanamine, and pharmacologically acceptable salts thereof, have been found to have substantial diuretic, natriuretic, but little, if any, kaliuretic activity, which can be used alone, or concomittently with other diuretic drugs such as furosemide or hydrochlorothiazide and/or with antihypertensive agents such as propranolol, captopril, minoxidil, prazosin, guanadrel sulfate, whose actions are supplemented by the action of a diuretic drug.

  公式为##STR1##的Triazolo-benzodiazepine-1-ethanamines，其中R，R.sub.1，R.sub.2，R.sub.3，R.sub.4和环A的定义如规范中所述，例如8-氯-N，N-二甲基-β，6-二苯基-4H-[1，2，4]三唑[4，3-a][1,4]苯并二氮平-1-乙胺及其药理学上可接受的盐，已发现具有显著的利尿、钠利尿作用，但几乎没有钾利尿作用，可单独使用，或与其他利尿药物如呋塞米或氢氯噻嗪和/或降压药物如普萘洛尔、卡托普利、米诺地尔、普拉索辛、磺酸冠脲等同时使用，这些药物的作用通过利尿药物的作用得到补充。
• 1-Ethanamine-triazolo-benzodiazepines as diuretics
  申请人：The Upjohn Company

  公开号：US04514407A1

  公开（公告）日：1985-04-30

  Triazolo-benzodiazepine-1-ethanamines of the formulas ##STR1## where R, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and Ring A are as defined in the specification, e.g., 8-chloro-N,N-dimethyl-.beta.,6-diphenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benz odiazepine-1-ethanamine, and pharmacologically acceptable salts thereof, have been found to have substantial diuretic, natriuretic, but little, if any, kaliuretic activity, which can be used alone, or concomittently with other diuretic drugs such as furosemide or hydrochlorothiazide and/or with antihypertensive agents such as propranolo, captopril, minoxidil, prazosin, guanadrel sulfate, whose actions are supplemented by the action of a diuretic drug.

  公式为##STR1##的Triazolo-benzodiazepine-1-ethanamines，其中R、R.sub.1、R.sub.2、R.sub.3、R.sub.4和Ring A的定义如规范中所述，例如8-氯-N，N-二甲基-β，6-二苯基-4H-[1,2,4]三唑并[4,3-a][1,4]苯并二氮平-1-乙胺，及其药理学上可接受的盐，已被发现具有显著的利尿、钠利尿作用，但很少有钾利尿作用，可以单独使用，或与其他利尿药物如呋塞米或氢氯噻嗪和/或抗高血压药物如普萘洛尔、卡托普利、米诺地尔、哌唑嗪、磺酸冠脲和其他利尿药物的作用相辅相成。